Literature DB >> 25085898

Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.

Olga Vornicova1, Dov Hershkovitz2, Tamar Yablonski-Peretz3, Ofer Ben-Itzhak2, Zohar Keidar4, Gil Bar-Sela1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25085898      PMCID： PMC4153459          DOI： 10.1634/theoncologist.2014-0054

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  9 in total

1.  Cytoreductive combination chemotherapy for regionally advanced unresectable extramammary Paget carcinoma.

Authors:  H Voigt; R Bassermann; W Nathrath
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

2.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Authors:  Heidi Greulich; Bethany Kaplan; Philipp Mertins; Tzu-Hsiu Chen; Kumiko E Tanaka; Cai-Hong Yun; Xiaohong Zhang; Se-Hoon Lee; Jeonghee Cho; Lauren Ambrogio; Rachel Liao; Marcin Imielinski; Shantanu Banerji; Alice H Berger; Michael S Lawrence; Jinghui Zhang; Nam H Pho; Sarah R Walker; Wendy Winckler; Gad Getz; David Frank; William C Hahn; Michael J Eck; D R Mani; Jacob D Jaffe; Steven A Carr; Kwok-Kin Wong; Matthew Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

3.  Metastatic extramammary Paget's disease: dramatic response to combined modality treatment.

Authors:  L Balducci; M Athar; G F Smith; T Khansur; D McKenzie; E D Crawford
Journal:  J Surg Oncol       Date:  1988-05       Impact factor: 3.454

4.  Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.

Authors:  Toru Ogawa; Yoji Nagashima; Hidefumi Wada; Kazunori Akimoto; Yoshiyuki Chiba; Tetsuo Nagatani; Yoshiaki Inayama; Masahiro Yao; Ichiro Aoki; Zenro Ikezawa
Journal:  Hum Pathol       Date:  2005-10-28       Impact factor: 3.466

5.  erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease.

Authors:  M Takata; A Fujimoto; H Aoki; N Hatta; A Ooi; K Takehara
Journal:  J Invest Dermatol       Date:  1999-08       Impact factor: 8.551

6.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

7.  Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.

Authors:  Shunsuke Takahagi; Hideki Noda; Akiko Kamegashira; Naoki Madokoro; Ikuko Hori; Hajime Shindo; Shouji Mihara; Michihiro Hide
Journal:  J Dermatol       Date:  2009-08       Impact factor: 4.005

8.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

9.  A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy.

Authors:  Fumie Hanawa; Takashi Inozume; Kazutoshi Harada; Tatsuyosi Kawamura; Naotaka Shibagaki; Shinji Shimada
Journal:  Case Rep Dermatol       Date:  2011-10-11
  9 in total
  13 in total

1.  Spinal Metastases of Extramammary Paget Disease with Radiologic-Pathologic Correlation.

Authors:  Jason T Little; Vance T Lehman; Jonathan M Morris; Julia S Lehman; Felix E Diehn
Journal:  J Radiol Case Rep       Date:  2016-05-31

2.  Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.

Authors:  Jian Wang; Yuxin Wen; Guanggui Ding; Peikun Ding; Lu Zhang; Jing Liu; Tengfei Zhang; Lin Yang
Journal:  Cancer Biol Ther       Date:  2018-04-12       Impact factor: 4.742

3.  Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

Authors:  Juliann Chmielecki; Jeffrey S Ross; Kai Wang; Garrett M Frampton; Gary A Palmer; Siraj M Ali; Norma Palma; Deborah Morosini; Vincent A Miller; Roman Yelensky; Doron Lipson; Philip J Stephens
Journal:  Oncologist       Date:  2014-12-05

4.  Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

Authors:  Wenhsiang Wen; Wangjuh Sting Chen; Nick Xiao; Ryan Bender; Anatole Ghazalpour; Zheng Tan; Jeffrey Swensen; Sherri Z Millis; Gargi Basu; Zoran Gatalica; Michael F Press
Journal:  J Mol Diagn       Date:  2015-09       Impact factor: 5.568

5.  Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

Authors:  Peter Barth; Essel Dulaimi Al-Saleem; Kristin W Edwards; Sherri Z Millis; Yu-Ning Wong; Daniel M Geynisman
Journal:  Case Rep Oncol Med       Date:  2015-01-27

6.  Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.

Authors:  Zoran Gatalica; Semir Vranic; Božo Krušlin; Kelsey Poorman; Phillip Stafford; Denisa Kacerovska; Wijendra Senarathne; Elena Florento; Elma Contreras; Alexandra Leary; April Choi; Gino K In
Journal:  Cancer Med       Date:  2020-01-03       Impact factor: 4.452

7.  An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers.

Authors:  June Y Hou; Jason D Wright; Vuthinun Achariyapota
Journal:  Gynecol Oncol Rep       Date:  2020-05-01

8.  Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.

Authors:  Maryam Pourmaleki; Jonathan H Young; Nicholas D Socci; Sarah Chiang; Marcia Edelweiss; Yanyun Li; Mianlei Zhang; Lev Roshal; Dennis S Chi; Klaus J Busam; Ingo K Mellinghoff; Travis J Hollmann
Journal:  Oncotarget       Date:  2019-10-22

9.  The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.

Authors:  Jung Won Shin; Soohyun Kim; Suji Ha; Byungsan Choi; Seongyeong Kim; Seock-Ah Im; Tae-Young Yoon; Junho Chung
Journal:  Biomolecules       Date:  2019-10-19

Review 10.  Analysis of different HER-2 mutations in breast cancer progression and drug resistance.

Authors:  Zijia Sun; Yaqin Shi; Yan Shen; Lulu Cao; Wenwen Zhang; Xiaoxiang Guan
Journal:  J Cell Mol Med       Date:  2015-08-25       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.